BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL)
NCT00088530
Completed
BBR 2778 is a novel aza-anthracenedione that has activity in experimental tumors and shows reduced potential for cardiotoxicity in animal models. This cytotoxic agent has structural similarities with mitoxantrone as well as general similarities with anthracyclines (such as the tricyclic central quinoid chromophore).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/27/2020
Locations: Robert A. Moss, M.D., FACP, Inc., Fountain Valley, California +98 locations
Conditions: Lymphoma, Non-Hodgkin
Register for Updates
A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer
NCT02117024
Terminated
Determine whether viagenpumatucel-L combined with low-dose cyclophosphamide prolongs survival in patients with NSCLC who failed 2 or 3 prior lines of therapy for incurable or metastatic disease compared with chemotherapy alone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/24/2020
Locations: Highlands Oncology Group, Rogers, Arkansas +15 locations
Conditions: Non Small Cell Lung Cancer
Register for Updates
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
NCT02383212
Completed
This is a phase 1, open-label, multicenter, ascending-dose escalation study of cemiplimab, alone and in combination with other anti-cancer therapies in patients with advanced malignancies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/23/2020
Locations: Banner MD Anderson Cancer Center, Gilbert, Arizona +46 locations
Conditions: Advanced Cancer, Advanced Malignancies
Register for Updates
Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma
NCT01731886
Completed
The study is being done to compare the combination of lenalidomide and dexamethasone followed by autologous peripheral blood stem cell transplant (PBSCT) and lenalidomide and dexamethasone without PBSCT in patients with untreated multiple myeloma. This comparison will include how the subjects respond to each study treatment combination, and what side effects are caused by each combination.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/21/2020
Locations: Columbia University, New York, New York
Conditions: Multiple Myeloma
Register for Updates
Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma
NCT00005803
Completed
This phase I/II trial studies how well autologous stem cell transplant followed by donor stem cell transplant works in treating patients with lymphoma that has returned or does not respond to treatment. Peripheral blood stem cell transplant using stem cells from the patient or a donor may be able to replace immune cells that were destroyed by chemotherapy used to kill cancer cells. The donated stem cells may also help destroy any remaining cancer cells (graft-versus-tumor effect).
Gender:
ALL
Ages:
75 years and below
Trial Updated:
01/17/2020
Locations: Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah +4 locations
Conditions: Prolymphocytic Leukemia, Recurrent Adult Hodgkin Lymphoma, Recurrent Childhood Hodgkin Lymphoma, Recurrent Childhood Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Non-Hodgkin Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Childhood Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Small Lymphocytic Lymphoma, T-Cell Chronic Lymphocytic Leukemia, T-Cell Prolymphocytic Leukemia
Register for Updates
Vincristine, Doxorubicin, Cyclophosphamide and Dexrazoxane (VACdxr) in High Risk Ewing's Sarcoma Patients
NCT00038142
Terminated
Objectives: 1. To determine if dose intensive Vincristine, Doxorubicin, Cyclophosphamide and Dexrazoxane (VACdxr) with or without ImmTherTM can improve the 2-year disease-free survival seen with standard VAC therapy. 2. To evaluate the feasibility and describe the toxicity associated with VACdxr. 3. To evaluate the feasibility and describe the toxicity of administering ImmTherTM on a weekly basis for 50- 52 weeks. 4. To determine which therapy (VACdxr+ or VACdxr-) is worthy of further evaluatio... Read More
Gender:
ALL
Ages:
Between 3 years and 60 years
Trial Updated:
01/17/2020
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Ewing's Sarcoma
Register for Updates
Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant, Mycophenolate Mofetil, and Cyclosporine in Treating Patients With Fanconi Anemia
NCT00453388
Completed
This phase II trial studies how well total-body irradiation (TBI) works when given together with fludarabine phosphate and cyclophosphamide followed by donor bone marrow transplant, mycophenolate mofetil, and cyclosporine in treating patients with Fanconi anemia (FA). Giving low doses of chemotherapy, such as fludarabine phosphate and cyclophosphamide, and TBI before or after a donor bone marrow transplant helps stop the growth of abnormal cells. It may also stop the patient's immune system from... Read More
Gender:
ALL
Ages:
All
Trial Updated:
01/17/2020
Locations: Children's Hospital and Research Center at Oakland, Oakland, California +4 locations
Conditions: Acute Myeloid Leukemia in Remission, de Novo Myelodysplastic Syndrome, Fanconi Anemia, Previously Treated Myelodysplastic Syndrome
Register for Updates
Bone Marrow Transplant From Related Donor for Patients With High Risk Hemoglobinopathies
NCT00040469
Terminated
The major goal of this study is to determine the risks and benefits of bone marrow transplants in patients with severe thalassemia or sickle cell disease. Participation in this project will be for two years.
Gender:
ALL
Ages:
Between 1 day and 64 years
Trial Updated:
01/15/2020
Locations: Texas Children's Hospital, Houston, Texas +1 locations
Conditions: Sickle Cell Anemia, Hemoglobinopathy, Thalassemia
Register for Updates
High Dose Chemo/Radiotherapy and Hematopoietic Stem Cell Transplant for Patients With Multiple Sclerosis
NCT00040482
Completed
Multiple Sclerosis is a disease that may be caused by the immune system reacting against the nervous system. It is possible, that by changing the immune system we can modify the progression of this disease. In this study, we will try to learn whether treatment with a bone marrow transplant (BMT) can help patients with multiple sclerosis. We will also try to learn what the side effects are of this treatment in patients with multiple sclerosis.
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
01/15/2020
Locations: The Methodist Hospital, Houston, Texas
Conditions: Multiple Sclerosis
Register for Updates
Anti-Human CD45 Monoclonal Antibodies in Patients With Advanced Leukemia Prior to Allogeneic Stem Cell Transplantation
NCT00057005
Completed
Participants in this study have a hematologic malignancy which is a disorder in the bone marrow that affects the body's ability to create blood. Participants might benefit from receiving an allogeneic stem cell transplant (meaning the cells come from a donor). The participants donor is a family member. Stem cells are cells in the bone marrow and blood that can form a whole new blood system.
Gender:
ALL
Ages:
45 years and below
Trial Updated:
01/15/2020
Locations: Texas Children's Hospital, Houston, Texas +1 locations
Conditions: LEUKEMIA
Register for Updates
Stem Cell Transplant to Treat Patients With Systemic Sclerosis
NCT00058578
Completed
Systemic Sclerosis is a disease that may be caused by the immune system reacting against skin and certain organs. It is possible, that by changing the immune system we can modify the progression of this disease. Stem cells are created in the bone marrow. They mature into different types of blood cells that are needed including red blood cells, white blood cells, and platelets. In this study, we will stimulate the bone marrow to make extra stem cells. Next we will collect the stem cells, select... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
01/15/2020
Locations: The Methodist Hospital, Houston, Texas
Conditions: Systemic Sclerosis
Register for Updates
T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts
NCT00368355
Completed
Subjects are being asked to participate in this study because treatment of their disease requires them to receive a stem cell transplant. Stem cells or "mother" cells are the source of normal blood cells and lead to recovery of blood counts after bone marrow transplantation (BMT). Unfortunately, there is not a perfectly matched stem cell donor (like a sister or brother) and the subject's disease is considered rapidly progressive and does not permit enough time to identify another donor (like som... Read More
Gender:
ALL
Ages:
55 years and below
Trial Updated:
01/15/2020
Locations: Houston Methodist Hospital, Houston, Texas +1 locations
Conditions: Acute Lymphoblastic Leukemia, Non Hodgkins Lymphoma, Myelodysplastic Syndrome, Acute Myeloid Leukemia, Chronic Myelogenous Leukemia, Hemophagocytic Lymphohistiocytosis (HLH), Familial Hemophagocytic Lymphohistiocytosis (FLH), Viral-associated Hemophagocytic Syndrome (VAHS), X-linked Lymphoproliferative Disease (XLP)
Register for Updates